Trial Profile

A Phase 2B, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (FASCINATE-2)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 May 2025 Primary endpoint related to safety has been cancelled. Timeframe for both the efficacy endpoints has been updated to 52 weeks.
23 Apr 2025 According to a Sagimet Biosciences media release, company will present data from this study in multiple poster presentation at the European Association for the Study of Liver (EASL) Congress 2025 being held May 7-10, 2025 in Amsterdam, Netherlands.
12 Mar 2025 According to a Sagimet Biosciences media release, the company presented clinical denifanstat and preclinical FASN inhibitor data at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting 2024, through an oral and a poster presentation in November 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com